Pfizer Inc. (PFE)
Pfizer Stock: It May Be Just The Beginning Of A Solid Rally
I initiated a "Buy" rating on Pfizer stock in February 2024, and since then, it's aging well. I believe the recovery rally in PFE stock may be just the beginning. The cost management initiatives seem to be progressing faster and more efficiently than one would have thought a few quarters ago - the solid Q2 numbers show that. Wall Street analysts are still giving very modest EPS growth projections for the next few years, creating a ground for possible EPS beating in the next quarters.
Pfizer Just Confirmed It's a Dividend Investor's Dream Stock
Pfizer's management is committed to maintaining and growing the dividend. The big drugmaker's dividend should be even more secure thanks to coming bottom-line improvements.
Pfizer to Buy a GLP-1 Drugmaker? Here's Why You Shouldn't Count on That Happening
CEO Albert Bourla doesn't see the company making a big acquisition for a GLP-1 drugmaker. Pfizer has close to $70 billion in long-term debt on its books.
Pfizer Just Did This for the First Time in 6 Quarters. Time to Buy?
Pfizer's earnings soared earlier in the pandemic, thanks to its blockbuster coronavirus vaccine and treatment. Since, revenue has dropped -- but Pfizer has made major efforts to return to growth.
Pfizer's Diverse Portfolio And Strong Execution Earn Analyst Praise Despite Patent Concerns
On Tuesday, Pfizer Inc. PFE reported second-quarter adjusted EPS of $0.60, down 11% year over year, beating the consensus of $0.46.
Merck / Pfizer Earnings Summaries: Staying With Merck For Now, Pfizer's Cost-Cutting Will Help Margins
The prime culprit for yesterday's 9.8% drop in Merck was what seemed to be a rather slight slip in Gardasil revenue – Merck's HPV vaccine – which came in about $20 million below consensus. At $113 – $115 per share, MRK is now trading at 14x and 12x 2024 and 2025 consensus estimates for expected growth this year that compares to '22 $7.48 in EPS. Pfizer reported a good quarter yesterday, with a 2% revenue beat and a 30% EPS for y-o-y growth of 2%, 9% operating income growth and -2% decline in EPS.
Pfizer Posts First Quarterly Revenue Growth Since Peak COVID Vaccine Sales
Pfizer (PFE) shares rose Tuesday after the pharmaceutical giant beat second-quarter revenue expectations and raised its full-year guidance.
Stock Of The Day: Pfizer Pattern Offers Lessons After Better-Than-Expected Q2 Results
Like many things on Wall Street, technical analysis is widely misunderstood. Many analysts try to identify chart patterns without understanding the psychology and price action that creates them.
Pfizer (PFE) Beats on Q2 Earnings & Sales, Raises 2024 View
Pfizer (PFE) beats second-quarter estimates for earnings and sales. It raises 2024 earnings as well as revenue expectations.
Here's What Key Metrics Tell Us About Pfizer (PFE) Q2 Earnings
The headline numbers for Pfizer (PFE) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Pfizer (PFE) Tops Q2 Earnings and Revenue Estimates
Pfizer (PFE) came out with quarterly earnings of $0.60 per share, beating the Zacks Consensus Estimate of $0.45 per share. This compares to earnings of $0.67 per share a year ago.
Pfizer Stock Rises After Guidance Hike, Earnings Beat.
Drugmaker Pfizer reported quarterly earnings above expectations on Tuesday as it raised full year guidance on the back of strong sales of non-Covid products.
